Ilyas Sahin Shared NEJM Article on Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia
Ilyas Sahin, Medical Oncologist at Massachusetts General Hospital, shared a post on X:
“A major advance in CLL!!!
Ibrutinib + venetoclax led to deeper remissions and better outcomes than ibrutinib alone or FCR (phase 3).
5-year progression-free survival: 94% vs. 79% vs. 58%
Fewer deaths: 4.2% vs. 9.9% vs. 14.8%
More durable responses, fewer relapses.”
Title: Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
Authors: Talha Munir, Sean Girvan, David Cairns, Adrian Bloor, David Allsup, Abraham Varghese, Satyen Gohil, Shankara Paneesha, Andrew Pettitt, Toby Eyre, Christopher Fox, Francesco Forconi, Constantine Balotis, Nicholas Pemberton, Oonagh Sheehy, John Gribben, Nagah Elmusharaf, Simona Gatto, Gavin Preston, Anna Schuh, Renata Walewska, Lelia Duley, Nichola Webster, Surita Dalal, Andrew Rawstron, Dena Howard, Anna Hockaday, Sharon Jackson, Natasha Greatorex, Sue Bell, David Stones, Julia Brown, Piers Patten, Peter Hillmen
You can read the Full Article on The New England Journal of Medicine
More posts featuring Chronic Lymphocytic Leukemia
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023